CAMBRIDGE, Mass.--(BUSINESS WIRE)--Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) today announced three presentations at the Society of Nuclear Medicine (SNM) 55th Annual Meeting on preclinical data supporting its Trofex program for the detection, staging and monitoring of prostate cancer. The presentations described the synthesis, production and preclinical profile of two lead candidate compounds, MIP-1072 and MIP-1095. These compounds provide the foundation for the Company’s recently initiated clinical program and support Molecular Insight’s small molecule approach to the discovery and development of molecular imaging pharmaceuticals. Molecular Insight is conducting an exploratory clinical trial with the two lead candidates with the goal of selecting a compound for further commercial development.
